Extra-thymically induced regulatory T cells: Do they have potential in disease prevention?

Seminars in Immunology

Volumn 23, Issue 6, 2011, Pages 410-417

  Daniel, Carolin ^a,b   Von Boehmer, Harald ^a,c  

^a DANA FARBER CANCER INSTITUTE   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c HARVARD UNIVERSITY   (United States)

Author keywords

Autoimmune disease; Conversion; Foxp3; Regulatory T cells; Vaccination

Indexed keywords

AUTOANTIGEN; EPITOPE; LIGAND; TRANSCRIPTION FACTOR FOXP3;

ANTIGEN SPECIFICITY; AUTOIMMUNE DISEASE; AUTOIMMUNITY; IMMUNE RESPONSE; IMMUNOLOGICAL TOLERANCE; IMMUNOPATHOLOGY; INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; REGULATORY T LYMPHOCYTE; REVIEW; THYMUS; VACCINATION;

ANIMALS; AUTOIMMUNE DISEASES; CELL DIFFERENTIATION; HUMANS; IMMUNE TOLERANCE; T-LYMPHOCYTES, REGULATORY; THYMUS GLAND; VACCINATION;

EID: 82755161015     PISSN: 10445323     EISSN: 10963618     Source Type: Journal    
DOI: 10.1016/j.smim.2011.06.004     Document Type: Review

References (129)

1. Burnet F.M. The clonal selection theory 1959, Cambridge Press, UK.
2. Lederberg J. Genes and antibodies. Science 1959, 129(June (3364)):1649-1653.
3. Kisielow P., Bluthmann H., Staerz U.D., Steinmetz M., von Boehmer H. Tolerance in T-cell-receptor transgenic mice involves deletion of nonmature CD4+8+ thymocytes. Nature 1988, 333(June (6175)):742-746.
4. Kappler J.W., Roehm N., Marrack P. T cell tolerance by clonal elimination in the thymus. Cell 1987, 49(April (2)):273-280.
5. Ramsdell F., Fowlkes B.J. Clonal deletion versus clonal anergy: the role of the thymus in inducing self tolerance. Science 1990, 248(June (4961)):1342-1348.
6. Derbinski J., Schulte A., Kyewski B., Klein L. Promiscuous gene expression in medullary thymic epithelial cells mirrors the peripheral self. Nat Immunol 2001, 2(November (11)):1032-1039.
7. Jolicoeur C., Hanahan D., Smith K.M. T-cell tolerance toward a transgenic beta-cell antigen and transcription of endogenous pancreatic genes in thymus. Proc Natl Acad Sci U S A 1994, 91(July (14)):6707-6711.
8. Bonasio R., Scimone M.L., Schaerli P., Grabie N., Lichtman A.H., von Andrian U.H. Clonal deletion of thymocytes by circulating dendritic cells homing to the thymus. Nat Immunol 2006, 7(October (10)):1092-1100.
9. Rocha B., von Boehmer H. Peripheral selection of the T cell repertoire. Science 1991, 251(March (4998)):1225-1228.
10. Rocha B., Tanchot C., von Boehmer H. Clonal anergy blocks in vivo growth of mature T cells and can be reversed in the absence of antigen. J Exp Med 1993, 177(May (5)):1517-1521.
11. Ohki H., Martin C., Corbel C., Coltey M., Le Douarin N.M. Tolerance induced by thymic epithelial grafts in birds. Science 1987, 237(Aug (4818)):1032-1035.
12. Salaun J., Bandeira A., Khazaal I., Calman F., Coltey M., Coutinho A., et al. Thymic epithelium tolerizes for histocompatibility antigens. Science 1990, 247(March (4949 Pt 1)):1471-1474.
13. Fontenot J.D., Gavin M.A., Rudensky A.Y. Foxp3 programs the development and function of CD4+CD25+ regulatory T cells. Nat Immunol 2003, 4(April (4)):330-336.
14. Khattri R., Cox T., Yasayko S.A., Ramsdell F. An essential role for Scurfin in CD4+CD25+ T regulatory cells. Nat Immunol 2003, 4(April (4)):337-342.
15. Brunkow M.E., Jeffery E.W., Hjerrild K.A., Paeper B., Clark L.B., Yasayko S.A., et al. Disruption of a new forkhead/winged-helix protein, scurfin, results in the fatal lymphoproliferative disorder of the scurfy mouse. Nat Genet 2001, 27(January (1)):68-73.
16. Chatila T.A., Blaeser F., Ho N., Lederman H.M., Voulgaropoulos C., Helms C., et al. JM2, encoding a fork head-related protein, is mutated in X-linked autoimmunity-allergic disregulation syndrome. J Clin Invest 2000, 106(December (12)):R75-R81.
17. Kim J.M., Rasmussen J.P., Rudensky A.Y. Regulatory T cells prevent catastrophic autoimmunity throughout the lifespan of mice. Nat Immunol 2007, 8(February (2)):191-197.
18. Lahl K., Loddenkemper C., Drouin C., Freyer J., Arnason J., Eberl G., et al. Selective depletion of Foxp3+ regulatory T cells induces a scurfy-like disease. J Exp Med 2007, 204(January (1)):57-63.
19. Apostolou I., Sarukhan A., Klein L., von Boehmer H. Origin of regulatory T cells with known specificity for antigen. Nat Immunol 2002, 3(August (8)):756-763.
20. Aschenbrenner K., D'Cruz L.M., Vollmann E.H., Hinterberger M., Emmerich J., Swee L.K., et al. Selection of Foxp3+ regulatory T cells specific for self antigen expressed and presented by Aire+ medullary thymic epithelial cells. Nat Immunol 2007, 8(April (4)):351-358.
21. Liston A., Nutsch K.M., Farr A.G., Lund J.M., Rasmussen J.P., Koni P.A., et al. Differentiation of regulatory Foxp3+ T cells in the thymic cortex. Proc Natl Acad Sci U S A 2008, 105(August (33)):11903-11908.
22. Gavin M.A., Rasmussen J.P., Fontenot J.D., Vasta V., Manganiello V.C., Beavo J.A., et al. Foxp3-dependent programme of regulatory T-cell differentiation. Nature 2007, 445(February (7129)):771-775.
23. Lin W., Haribhai D., Relland L.M., Truong N., Carlson M.R., Williams C.B., et al. cell development in the absence of functional Foxp3. Nat Immunol 2007, 8(April (4)):359-368.
24. Bautista J.L., Lio C.W., Lathrop S.K., Forbush K., Liang Y., Luo J., et al. Intraclonal competition limits the fate determination of regulatory T cells in the thymus. Nat Immunol 2009, 10(June (6)):610-617.
25. Leung M.W., Shen S., Lafaille J.J. TCR-dependent differentiation of thymic Foxp3+ cells is limited to small clonal sizes. J Exp Med 2009, 206(September (10)):2121-2130.
26. Hsieh C.S., Liang Y., Tyznik A.J., Self S.G., Liggitt D., Rudensky A.Y. Recognition of the peripheral self by naturally arising CD25+ CD4+ T cell receptors. Immunity 2004, 21(August (2)):267-277.
27. Tai X., Cowan M., Feigenbaum L., Singer A. CD28 costimulation of developing thymocytes induces Foxp3 expression and regulatory T cell differentiation independently of interleukin 2. Nat Immunol 2005, 6(February (2)):152-162.
28. Apostolou I., von Boehmer H. In vivo instruction of suppressor commitment in naive T cells. J Exp Med 2004, 199(May (10)):1401-1408.
29. Kretschmer K., Apostolou I., Hawiger D., Khazaie K., Nussenzweig M.C., von Boehmer H. Inducing and expanding regulatory T cell populations by foreign antigen. Nat Immunol 2005, 6(December (12)):1219-1227.
30. Mathis D., Benoist C. A decade of AIRE. Nat Rev Immunol 2007, 7(August (8)):645-650.
31. Hsieh C.S., Rudensky A.Y. The role of TCR specificity in naturally arising CD25+ CD4+ regulatory T cell biology. Curr Top Microbiol Immunol 2005, 293:25-42.
32. Pacholczyk R., Ignatowicz H., Kraj P., Ignatowicz L. Origin and T cell receptor diversity of Foxp3+CD4+CD25+ T cells. Immunity 2006, 25(August (2)):249-259.
33. Salomon B., Lenschow D.J., Rhee L., Ashourian N., Singh B., Sharpe A., et al. B7/CD28 costimulation is essential for the homeostasis of the CD4+CD25+ immunoregulatory T cells that control autoimmune diabetes. Immunity 2000, 12(April (4)):431-440.
34. Tang Q., Henriksen K.J., Boden E.K., Tooley A.J., Ye J., Subudhi S.K., et al. Cutting edge: CD28 controls peripheral homeostasis of CD4+CD25+ regulatory T cells. J Immunol 2003, 171(October (7)):3348-3352.
35. Holdorf A.D., Green J.M., Levin S.D., Denny M.F., Straus D.B., Link V., et al. Proline residues in CD28 and the Src homology (SH)3 domain of Lck are required for T cell costimulation. J Exp Med 1999, 190(August (3)):375-384.
36. Holdorf A.D., Lee K.H., Burack W.R., Allen P.M., Shaw A.S. Regulation of Lck activity by CD4 and CD28 in the immunological synapse. Nat Immunol 2002, 3(March (3)):259-264.
37. Almeida A.R., Legrand N., Papiernik M., Freitas A.A. Homeostasis of peripheral CD4+ T cells: IL-2R alpha and IL-2 shape a population of regulatory cells that controls CD4+ T cell numbers. J Immunol 2002, 169(November (9)):4850-4860.
38. Kramer S., Schimpl A., Hunig T. Immunopathology of interleukin (IL) 2-deficient mice: thymus dependence and suppression by thymus-dependent cells with an intact IL-2 gene. J Exp Med 1995, 182(December (6)):1769-1776.
39. Schorle H., Holtschke T., Hunig T., Schimpl A., Horak I. Development and function of T cells in mice rendered interleukin-2 deficient by gene targeting. Nature 1991, 352(August (6336)):621-624.
40. Suzuki H., Kundig T.M., Furlonger C., Wakeham A., Timms E., Matsuyama T., et al. Deregulated T cell activation and autoimmunity in mice lacking interleukin-2 receptor beta. Science 1995, 268(June (5216)):1472-1476.
41. Suzuki H., Zhou Y.W., Kato M., Mak T.W., Nakashima I. Normal regulatory alpha/beta T cells effectively eliminate abnormally activated T cells lacking the interleukin 2 receptor beta in vivo. J Exp Med 1999, 190(December (11)):1561-1572.
42. Bayer A.L., Yu A., Adeegbe D., Malek T.R. Essential role for interleukin-2 for CD4(+)CD25(+) T regulatory cell development during the neonatal period. J Exp Med 2005, 201(March (5)):769-777.
43. Setoguchi R., Hori S., Takahashi T., Sakaguchi S. Homeostatic maintenance of natural Foxp3(+) CD25(+) CD4(+) regulatory T cells by interleukin (IL)-2 and induction of autoimmune disease by IL-2 neutralization. J Exp Med 2005, 201(March (5)):723-735.
44. D'Cruz L.M., Klein L. Development and function of agonist-induced CD25+Foxp3+ regulatory T cells in the absence of interleukin 2 signaling. Nat Immunol 2005, 6(November (11)):1152-1159.
45. Fontenot J.D., Rasmussen J.P., Gavin M.A., Rudensky A.Y. A function for interleukin 2 in Foxp3-expressing regulatory T cells. Nat Immunol 2005, 6(November (11)):1142-1151.
46. Chen W., Jin W., Hardegen N., Lei K.J., Li L., Marinos N., et al. Conversion of peripheral CD4+. J Exp Med 2003, 198(December (12)):1875-1886.
47. Li M.O., Flavell R.A. TGF-beta: a master of all T cell trades. Cell 2008, 134(August (3)):392-404.
48. Zheng S.G., Gray J.D., Ohtsuka K., Yamagiwa S., Horwitz D.A. Generation ex vivo of TGF-beta-producing regulatory T cells from CD4+CD25- precursors. J Immunol 2002, 169(October (8)):4183-4189.
49. Li M.O., Sanjabi S., Flavell R.A. Transforming growth factor-beta controls development, homeostasis, and tolerance of T cells by regulatory T cell-dependent and -independent mechanisms. Immunity 2006, 25(September (3)):455-471.
50. Marie J.C., Letterio J.J., Gavin M., Rudensky A.Y. TGF-beta1 maintains suppressor function and Foxp3 expression in CD4+CD25+ regulatory T cells. J Exp Med 2005, 201(April (7)):1061-1067.
51. Marie J.C., Liggitt D., Rudensky A.Y. Cellular mechanisms of fatal early-onset autoimmunity in mice with the T cell-specific targeting of transforming growth factor-beta receptor. Immunity 2006, 25(September (3)):441-454.
52. Liu Y., Zhang P., Li J., Kulkarni A.B., Perruche S., Chen W. A critical function for TGF-beta signaling in the development of natural CD4+CD25+Foxp3+ regulatory T cells. Nat Immunol 2008, 9(June (6)):632-640.
53. Ouyang W., Beckett O., Ma Q., Li M.O. Transforming growth factor-beta signaling curbs thymic negative selection promoting regulatory T cell development. Immunity 2010, 32(May (5)):642-653.
54. Chen C., Rowell E.A., Thomas R.M., Hancock W.W., Wells A.D. Transcriptional regulation by Foxp3 is associated with direct promoter occupancy and modulation of histone acetylation. J Biol Chem 2006, 281(December (48)):36828-36834.
55. Marson A., Kretschmer K., Frampton G.M., Jacobsen E.S., Polansky J.K., MacIsaac K.D., et al. Foxp3 occupancy and regulation of key target genes during T-cell stimulation. Nature 2007, 445(February (7130)):931-935.
56. Daniel C., Wennhold K., Kim H.J., von Boehmer H. Enhancement of antigen-specific Treg vaccination in vivo. Proc Natl Acad Sci U S A 2010, 107(September (37)):16246-16251.
57. Daniel C., Ploegh H., von Boehmer H. Antigen-specific induction of regulatory T cells in vivo and in vitro. Methods Mol Biol 2011, 707:173-185.
58. Verginis P., McLaughlin K.A., Wucherpfennig K.W., von Boehmer H., Apostolou I. Induction of antigen-specific regulatory T cells in wild-type mice: visualization and targets of suppression. Proc Natl Acad Sci U S A 2008, 105(March (9)):3479-3484.
59. Dietrich F.M., Weigle W.O. Induction of tolerance to heterologous proteins and their catabolism in C57BL/6 mice. J Exp Med 1963, 117(April):621-631.
60. Merkenschlager M., von Boehmer H. PI3 kinase signalling blocks Foxp3 expression by sequestering Foxo factors. J Exp Med 2010, 207(July (7)):1347-1350.
61. Sauer S., Bruno L., Hertweck A., Finlay D., Leleu M., Spivakov M., et al. T cell receptor signaling controls Foxp3 expression via PI3K, Akt, and mTOR. Proc Natl Acad Sci U S A 2008, 105(June (22)):7797-7802.
62. Josefowicz S.Z., Wilson C.B., Rudensky A.Y. Cutting edge: TCR stimulation is sufficient for induction of Foxp3 expression in the absence of DNA methyltransferase 1. J Immunol 2009, 182(June (11)):6648-6652.
63. Polansky J.K., Kretschmer K., Freyer J., Floess S., Garbe A., Baron U., et al. DNA methylation controls Foxp3 gene expression. Eur J Immunol 2008, 38(June (6)):1654-1663.
64. Rubtsov Y.P., Niec R.E., Josefowicz S., Li L., Darce J., Mathis D., et al. Stability of the regulatory T cell lineage in vivo. Science 2010, 329(September (5999)):1667-1671.
65. Klein L., Khazaie K., von Boehmer H. In vivo dynamics of antigen-specific regulatory T cells not predicted from behavior in vitro. Proc Natl Acad Sci U S A 2003, 100(July (15)):8886-8891.
66. Benson M.J., Pino-Lagos K., Rosemblatt M., Noelle R.J. All-trans retinoic acid mediates enhanced T reg cell growth, differentiation, and gut homing in the face of high levels of co-stimulation. J Exp Med 2007, 204(August (8)):1765-1774.
67. Coombes J.L., Siddiqui K.R., Arancibia-Carcamo C.V., Hall J., Sun C.M., Belkaid Y., et al. A functionally specialized population of mucosal CD103+ DCs induces Foxp3+ regulatory T cells via a TGF-beta and retinoic acid-dependent mechanism. J Exp Med 2007, 204(August (8)):1757-1764.
68. Mucida D., Pino-Lagos K., Kim G., Nowak E., Benson M.J., Kronenberg M., et al. Retinoic acid can directly promote TGF-beta-mediated Foxp3(+) Treg cell conversion of naive T cells. Immunity 2009, 30(April (4)):471-472.
69. Sun C.M., Hall J.A., Blank R.B., Bouladoux N., Oukka M., Mora J.R., et al. Small intestine lamina propria dendritic cells promote de novo generation of Foxp3T reg cells via retinoic acid. J Exp Med 2007, 204(August (8)):1775-1785.
70. Kim H.P., Leonard W.J. CREB/ATF-dependent T cell receptor-induced FoxP3 gene expression: a role for DNA methylation. J Exp Med 2007, 204(July (7)):1543-1551.
71. Tone Y., Furuuchi K., Kojima Y., Tykocinski M.L., Greene M.I., Tone M. Smad3 and NFAT cooperate to induce Foxp3 expression through its enhancer. Nat Immunol 2008, 9(February (2)):194-202.
72. Huehn J., Polansky J.K., Hamann A. Epigenetic control of FOXP3 expression: the key to a stable regulatory T-cell lineage?. Nat Rev Immunol 2009, 9(February (2)):83-89.
73. Zheng Y., Josefowicz S., Chaudhry A., Peng X.P., Forbush K., Rudensky A.Y. Role of conserved non-coding DNA elements in the Foxp3 gene in regulatory T-cell fate. Nature 2010, 463(February (7282)):808-812.
74. Baron U., Floess S., Wieczorek G., Baumann K., Grutzkau A., Dong J., et al. DNA demethylation in the human FOXP3 locus discriminates regulatory T cells from activated FOXP3(+) conventional T cells. Eur J Immunol 2007, 37(September (9)):2378-2389.
75. Floess S., Freyer J., Siewert C., Baron U., Olek S., Polansky J., et al. Epigenetic control of the foxp3 locus in regulatory T cells. PLoS Biol 2007, 5(February (2)):e38.
76. Zheng Y., Rudensky A.Y. Foxp3 in control of the regulatory T cell lineage. Nat Immunol 2007, 8(May (5)):457-462.
77. Josefowicz S.Z., Rudensky A. Control of regulatory T cell lineage commitment and maintenance. Immunity 2009, 30(May (5)):616-625.
78. Delgoffe G.M., Kole T.P., Zheng Y., Zarek P.E., Matthews K.L., Xiao B., et al. The mTOR kinase differentially regulates effector and regulatory T cell lineage commitment. Immunity 2009, 30(June (6)):832-844.
79. Wohlfert E.A., Gorelik L., Mittler R., Flavell R.A., Clark R.B. Cutting edge: deficiency in the E3 ubiquitin ligase Cbl-b results in a multifunctional defect in T cell TGF-beta sensitivity in vitro and in vivo. J Immunol 2006, 176(February (3)):1316-1320.
80. Haxhinasto S., Mathis D., Benoist C. The AKT-mTOR axis regulates de novo differentiation of CD4+Foxp3+ cells. J Exp Med 2008, 205(March (3)):565-574.
81. Harada Y., Harada Y., Elly C., Ying G., Paik J.H., DePinho R.A., et al. Transcription factors Foxo3a and Foxo1 couple the E3 ligase Cbl-b to the induction of Foxp3 expression in induced regulatory T cells. J Exp Med 2010, 207(July (7)):1381-1391.
82. Ouyang W., Beckett O., Ma Q., Paik J.H., DePinho R.A., Li M.O. Foxo proteins cooperatively control the differentiation of Foxp3+ regulatory T cells. Nat Immunol 2010, 11(July (7)):618-627.
83. Hedrick S.M. The cunning little vixen: Foxo and the cycle of life and death. Nat Immunol 2009, 10(October (10)):1057-1063.
84. Cobbold S.P., Adams E., Farquhar C.A., Nolan K.F., Howie D., Lui K.O., et al. Infectious tolerance via the consumption of essential amino acids and mTOR signaling. Proc Natl Acad Sci U S A 2009, 106(July (29)):12055-12060.
85. Mancini M., Petta S., Martinelli G., Barbieri E., Santucci M.A. RAD 001 (everolimus) prevents mTOR and Akt late re-activation in response to imatinib in chronic myeloid leukemia. J Cell Biochem 2010, 109(February (2)):320-328.
86. Powell J.D., Delgoffe G.M. The mammalian target of rapamycin: linking T cell differentiation, function, and metabolism. Immunity 2010, 33(September (3)):301-311.
87. Sarbassov D.D., Ali S.M., Sengupta S., Sheen J.H., Hsu P.P., Bagley A.F., et al. Prolonged rapamycin treatment inhibits mTORC2 assembly and Akt/PKB. Mol Cell 2006, 22(April (2)):159-168.
88. Zeng Z., Sarbassov d.D., Samudio I.J., Yee K.W., Munsell M.F., Ellen J.C., et al. Rapamycin derivatives reduce mTORC2 signaling and inhibit AKT activation in AML. Blood 2007, 109(April (8)):3509-3512.
89. Webster K.E., Walters S., Kohler R.E., Mrkvan T., Boyman O., Surh C.D., et al. In vivo expansion of T reg cells with IL-2-mAb complexes: induction of resistance to EAE and long-term acceptance of islet allografts without immunosuppression. J Exp Med 2009, 206(April (4)):751-760.
90. Fairchild P.J., Wildgoose R., Atherton E., Webb S., Wraith D.C. An autoantigenic T cell epitope forms unstable complexes with class II MHC: a novel route for escape from tolerance induction. Int Immunol 1993, 5(September (9)):1151-1158.
91. Garcia K.C., Teyton L., Wilson I.A. Structural basis of T cell recognition. Annu Rev Immunol 1999, 17:369-397.
92. Hahn M., Nicholson M.J., Pyrdol J., Wucherpfennig K.W. Unconventional topology of self peptide-major histocompatibility complex binding by a human autoimmune T cell receptor. Nat Immunol 2005, 6(May (5)):490-496.
93. He X.L., Radu C., Sidney J., Sette A., Ward E.S., Garcia K.C. Structural snapshot of aberrant antigen presentation linked to autoimmunity: the immunodominant epitope of MBP complexed with I-Au. Immunity 2002, 17(July (1)):83-94.
94. Liu G.Y., Fairchild P.J., Smith R.M., Prowle J.R., Kioussis D., Wraith D.C. Low avidity recognition of self-antigen by T cells permits escape from central tolerance. Immunity 1995, 3(October (4)):407-415.
95. Sethi D.K., Schubert D.A., Anders A.K., Heroux A., Bonsor D.A., Thomas C.P., et al. A highly tilted binding mode by a self-reactive T cell receptor results in altered engagement of peptide and MHC. J Exp Med 2011, 208(January (1)):91-102.
96. Stadinski B.D., Zhang L., Crawford F., Marrack P., Eisenbarth G.S., Kappler J.W. Diabetogenic T cells recognize insulin bound to IAg7 in an unexpected, weakly binding register. Proc Natl Acad Sci U S A 2010, 107(June (24)):10978-10983.
97. Jaeckel E., Lipes M.A., von Boehmer H. Recessive tolerance to preproinsulin 2 reduces but does not abolish type 1 diabetes. Nat Immunol 2004, 5(October (10)):1028-1035.
98. Nakayama M., Abiru N., Moriyama H., Babaya N., Liu E., Miao D., et al. Prime role for an insulin epitope in the development of type 1 diabetes in NOD mice. Nature 2005, 435(May (7039)):220-223.
99. Wegmann D.R., Norbury-Glaser M., Daniel D. Insulin-specific T cells are a predominant component of islet infiltrates in pre-diabetic NOD mice. Eur J Immunol 1994, 24(August (8)):1853-1857.
100. Daniel D., Gill R.G., Schloot N., Wegmann D. Epitope specificity, cytokine production profile and diabetogenic activity of insulin-specific T cell clones isolated from NOD mice. Eur J Immunol 1995, 25(April (4)):1056-1062.
101. Lee K.H., Wucherpfennig K.W., Wiley D.C. Structure of a human insulin peptide-HLA-DQ8 complex and susceptibility to type 1 diabetes. Nat Immunol 2001, 2(June (6)):501-507.
102. Acha-Orbea H., McDevitt H.O. The first external domain of the nonobese diabetic mouse class II I-A beta chain is unique. Proc Natl Acad Sci U S A 1987, 84(April (8)):2435-2439.
103. Todd J.A., Bell J.I., McDevitt H.O. HLA-DQ beta gene contributes to susceptibility and resistance to insulin-dependent diabetes mellitus. Nature 1987, 329(October (6140)):599-604.
104. Corper A.L., Stratmann T., Apostolopoulos V., Scott C.A., Garcia K.C., Kang A.S., et al. A structural framework for deciphering the link between I-Ag7 and autoimmune diabetes. Science 2000, 288(April (5465)):505-511.
105. Stadinski B.D., Delong T., Reisdorph N., Reisdorph R., Powell R.L., Armstrong M., et al. Chromogranin A is an autoantigen in type 1 diabetes. Nat Immunol 2010, 11(March (3)):225-231.
106. Bergman B., Haskins K. Islet-specific T-cell clones from the NOD mouse respond to beta-granule antigen. Diabetes 1994, 43(February (2)):197-203.
107. Wucherpfennig K.W., Sethi D. T cell receptor recognition of self and foreign antigens in the induction of autoimmunity. Semin Immunol 2011, (February).
108. Lu L.F., Boldin M.P., Chaudhry A., Lin L.L., Taganov K.D., Hanada T., et al. Function of miR-146a in controlling Treg cell-mediated regulation of Th1 responses. Cell 2010, 142(September (6)):914-929.
109. Daniel C., Weigmann B., Bronson R., von Boehmer H. Prevention of type 1 diabetes in mice by tolerogenic vaccination with a strong-agonist insulin mimetope. J Exp Med 2011, 10.1084/jem.20110574.
110. Gottschalk R.A., Corse E., Allison J.P. TCR ligand density and affinity determine peripheral induction of Foxp3 in vivo. J Exp Med 2010, 207(August (8)):1701-1711.
111. Stefanova I., Hemmer B., Vergelli M., Martin R., Biddison W.E., Germain R.N. TCR ligand discrimination is enforced by competing ERK positive and SHP-1 negative feedback pathways. Nat Immunol 2003, 4(March (3)):248-254.
112. Celli S., Garcia Z., Beuneu H., Bousso P. Decoding the dynamics of T cell-dendritic cell interactions in vivo. Immunol Rev 2008, February (221):182-187.
113. von Andrian U.H., Mempel T.R. Homing and cellular traffic in lymph nodes. Nat Rev Immunol 2003, 3(November (11)):867-878.
114. Steinman R.M., Hawiger D., Nussenzweig M.C. Tolerogenic dendritic cells. Annu Rev Immunol 2003, 21:685-711.
115. Henrickson S.E., Mempel T.R., Mazo I.B., Liu B., Artyomov M.N., Zheng H., et al. T cell sensing of antigen dose governs interactive behavior with dendritic cells and sets a threshold for T cell activation. Nat Immunol 2008, 9(March (3)):282-291.
116. Skokos D., Shakhar G., Varma R., Waite J.C., Cameron T.O., Lindquist R.L., et al. Peptide-MHC potency governs dynamic interactions between T cells and dendritic cells in lymph nodes. Nat Immunol 2007, 8(August (8)):835-844.
117. van der Merwe P.A., Dushek O. Mechanisms for T cell receptor triggering. Nat Rev Immunol 2011, 11(January (1)):47-55.
118. Acuto O., Cantrell D. T cell activation and the cytoskeleton. Annu Rev Immunol 2000, 18:165-184.
119. Irvine D.J., Purbhoo M.A., Krogsgaard M., Davis M.M. Direct observation of ligand recognition by T cells. Nature 2002, 419(October (6909)):845-849.
120. Zhang Z.J., Davidson L., Eisenbarth G., Weiner H.L. Suppression of diabetes in nonobese diabetic mice by oral administration of porcine insulin. Proc Natl Acad Sci U S A 1991, 88(November (22)):10252-10256.
121. Aspord C., Thivolet C. Nasal administration of CTB-insulin induces active tolerance against autoimmune diabetes in non-obese diabetic (NOD) mice. Clin Exp Immunol 2002, 130(November (2)):204-211.
122. Harrison L.C., Dempsey-Collier M., Kramer D.R., Takahashi K. Aerosol insulin induces regulatory CD8 gamma delta T cells that prevent murine insulin-dependent diabetes. J Exp Med 1996, 184(December (6)):2167-2174.
123. Chen W., Bergerot I., Elliott J.F., Harrison L.C., Abiru N., Eisenbarth G.S., et al. Evidence that a peptide spanning the B-C junction of proinsulin is an early Autoantigen epitope in the pathogenesis of type 1 diabetes. J Immunol 2001, 167(November (9)):4926-4935.
124. Daniel D., Wegmann D.R. Intranasal administration of insulin peptide B: 9-23 protects NOD mice from diabetes. Ann N Y Acad Sci 1996, February (778):371-372.
125. Martinez N.R., Augstein P., Moustakas A.K., Papadopoulos G.K., Gregori S., Adorini L., et al. Disabling an integral CTL epitope allows suppression of autoimmune diabetes by intranasal proinsulin peptide. J Clin Invest 2003, 111(May (9)):1365-1371.
126. Bergerot I., Ploix C., Petersen J., Moulin V., Rask C., Fabien N., et al. A cholera toxoid-insulin conjugate as an oral vaccine against spontaneous autoimmune diabetes. Proc Natl Acad Sci U S A 1997, 94(April (9)):4610-4614.
127. Orban T., Farkas K., Jalahej H., Kis J., Treszl A., Falk B., et al. Autoantigen-specific regulatory T cells induced in patients with type 1 diabetes mellitus by insulin B-chain immunotherapy. J Autoimmun 2010, 34(June (4)):408-415.
128. Alleva D.G., Gaur A., Jin L., Wegmann D., Gottlieb P.A., Pahuja A., et al. Immunological characterization and therapeutic activity of an altered-peptide ligand NBI-6024, based on the immunodominant type 1 diabetes autoantigen insulin B-chain (9-23) peptide. Diabetes 2002, 51(July (7)):2126-2134.
129. Pugliese A., Zeller M., Fernandez A., Zalcberg L.J., Bartlett R.J., Ricordi C., et al. The insulin gene is transcribed in the human thymus and transcription levels correlated with allelic variation at the INS VNTR-IDDM2 susceptibility locus for type 1 diabetes. Nat Genet 1997, 15(March (3)):293-297.